Flexion Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

BURLINGTON, Mass., Feb. 15, 2017 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, February 22, 2017 at 8:30 a.m. Eastern Time at The New York Palace Hotel. 

To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.

About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA). The company's lead product candidate, Zilretta^TM (FX006), is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive intra-articular injections for OA related knee pain annually.

Corporate Contacts:

Fred Driscoll
Chief Financial Officer
Flexion Therapeutics, Inc.
T: 781-305-7763
[email protected]

Scott Young
Sr. Director, Corporate Communications & Investor Relations
Flexion Therapeutics, Inc.
T: 781-305-7194
[email protected]